Table 3.

Daily estimation of serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), tumour necrosis factor-alpha (TNFα), interleukin-6 (IL-6) and IL-8 of 90 patients with septic syndrome in the filed of ventilator-associated pneumonia in relation to their final outcome.

	Survivors (n = 57)	Non-survivors (n = 33)	P-value
sTREM-1 (pg/ml, median-range)
Day 1	79·5 (15·1–997·6)	164·3 (15·1–513·8)	0·031
Day 2	83·0 (15·1–1054·5)	165·9 (15·1–912·2)	0·019
Day 3	80·4 (15·1–1145·8)	171·2 (15·1–902·4)	0·035
Day 4	75·6 (15·1–975·6)	168·7 (23·4–642·2)	0·002
Day 5	102·2 (15·1–763·2)	182·9 (15·1–1269·5)	NS
Day 6	91·5 (15·1–887·8)	163·3 (15·1–1630·5)	0·027
Day 7	90·0 (15·1–1041·2)	158·9 (15·1–978·1)	NS
TNFα (pg/ml, median-range)
Day 1	5·61 (0·70–42·97)	6·36 (0·45–20·98)	NS*
Day 2	5·29 (0·42–84·45)	8·76 (2·95–23·29)	NS
Day 3	5·19 (0·42–178·57)	10·46 (1·49–490·39)	NS
Day 4	5·27 (0·39–491·24)	6·36 (0·67–609·03)	NS
Day 5	5·32 (0·84–381·08)	7·21 (1·49–135·96)	0·044
Day 6	5·68 (1·35–786·07)	10·16 (2·68–75·23)	0·040
Day 7	5·62 (1·60–729·89)	9·15 (4·83–1801·62)	0·041
IL-6 (pg/ml, median-range)
Day 1	89·25 (12·76–256·55)	222·58 (15·60–347·05)	0·044
Day 2	85·23 (< 6·25–246·01)	90·30 (15·21–312·72)	NS
Day 3	85·24 (< 6·25–248·51)	170·18 (24·21–314·29)	< 0·0001
Day 4	79·32 (< 6·25–240·19)	165·71 (13·47–325·35)	0·005
Day 5	59·72 (< 6·25–264·97)	180·57 (< 6·25–336·46)	0·003
Day 6	58·05 (< 62·5–319·04)	156·57 (13·23–364·97)	< 0·0001
Day 7	53·80 (< 6·25–248·89)	206·79 (20·82–326·49)	< 0·0001
IL-8 (pg/ml, median-range)
Day 1	97·3 (< 62·5–1439·4)	63·66 (< 62·5–1716·9)	NS
Day 2	152·9 (< 62·5–1540·0)	< 62·5 (< 62·5–1617·6)	NS
Day 3	148·9 (< 62·5–1637·8)	< 62·5 (< 62·5–1614·7)	NS
Day 4	81·9 (< 62·5–1676·1)	< 62·5 (< 62·5–1886·8)	NS
Day 5	133·5 (< 62·5–1683·7)	< 62·5 (< 62·5–1560·1)	NS
Day 6	100.8 (< 62·5–1485·4)	< 62·5 (< 62·5–2594·8)	NS
Day 7	159·2 (< 62·5–1686·6)	148·8 (< 62·5–3013·2)	NS

^*NS, nonsignificant